

# Summary of 12wk CDAHFD w/ sIL13Ra2, anti-p40, and anti-IL4 or anti-TGFbeta



WORLDWIDE RESEARCH & DEVELOPMENT




# Experimental Design

**Objective:** Evaluate effects by various therapeutic combinations on fibrosis endpoints in CDAHFD NASH model in mice

**Duration** – 12wk, treatments start after 4 weeks

**Data collection:** weekly body weight, study end liver weight, study end serum liver enzyme, Real-time shear wave (SWE) elastography before and at week 4, 6, 8, 10 and 12 after on CDAHFD diet.



**Liver gene expression:** a-SMA, Col1a1, Col3a1, Col4a1, Col6a1, MCP-1, IL4, IL5, Siglec5, IL12, IL23


**Histopathology:** Liver - HE, aSMA IHC, Iba1 IHC, Picrosirius red (PSR)

Group ID	Animal ID	Diet	Compound	route	Duration
1	1_12	chow	none		12 wk
2	14_24	CDAHFD	mIgGs		12 wk
3	25_36	CDAHFD	sIL13Ra2, anti-p40		12 wk
4	37_44, 49_52	CDAHFD	anti-IL4, sIL13Ra2, anti-p40		12 wk
5	46_48, 53_60	CDAHFD	sIL13Ra2, anti-p40, anti-TGF-b	subQ, 2x/wk	12 wk
6	61_67	CDAHFD	none		4 wk



WORLDWIDE RESEARCH & DEVELOPMENT  
Drug Safety R&D

SCIENCE LIFE-CHANGING  
FOR IMPACT



WORLDWIDE RESEARCH & DEVELOPMENT  
Drug Safety R&D

SCIENCE  LIFE-CHANGING  
FOR IMPACT



# Note: exclusion of animals

- In CDAHFD studies, some mice, in both control diet group and CDAHFD diet group, will develop cirrhotic livers. The mechanism for this cirrhosis development is unknown, and we suspect it is related to the purified diets. All mice (4 out of 60 in this study - # 27,42,48,58) that developed cirrhosis were excluded from data analysis.



WORLDWIDE RESEARCH & DEVELOPMENT  
Drug Safety R&D

SCIENCE  LIFE-CHANGING  
FOR IMPACT



Reduced liver index (liver:body weight ratio) by both triple combinations

Statistics: treatments v.s. Ctrl IgG  
GraphPad one way ANOVA multiple comparisons






WORLDWIDE RESEARCH & DEVELOPMENT  
Drug Safety R&D

Cirrhotic liver excluded

SCIENCE LIFE-CHANGING  
FOR IMPACT

# Liver enzymes




WORLDWIDE RESEARCH & DEVELOPMENT  
Drug Safety R&D

Cirrhotic liver excluded

SCIENCE LIFE-CHANGING  
FOR IMPACT

# Liver gene expression



WORLDWIDE RESEARCH & DEVELOPMENT  
Drug Safety R&D


Statistics: treatments v.s. Ctrl IgG

GraphPad one way ANOVA multiple comparisons

SCIENCE LIFE-CHANGING  
FOR IMPACT

Cirrhotic liver excluded

# Liver gene expression




WORLDWIDE RESEARCH & DEVELOPMENT  
Drug Safety R&D

Cirrhotic liver excluded

SCIENCE LIFE-CHANGING  
FOR IMPACT




# Real-time shear wave elastography measurement of liver fibrosis (mice with cirrhotic liver excluded)




# Histology results and interpretations – Kate Hammerman


- The triple (TGFb) combination significantly reduced PSR, aSMA staining and increased Iba1 staining.
- There were small foci of hepatic necrosis and multifocal hepatocellular vacuolation in liver from individual control chow-fed animals; the necrosis may impact liver enzyme data in this group.



Statistics: GraphPad Prism,  
Kruskal-Wallis ANOVA with multiple  
comparisons (TA vs CDAHFD/IgG); NS=  
 $p > 0.05$



Statistics: GraphPad Prism,  
Kruskal-Wallis ANOVA with multiple  
comparisons (TA vs CDAHFD/IgG); NS=  
 $p > 0.05$



Statistics: GraphPad Prism,  
Kruskal-Wallis ANOVA with multiple  
comparisons (TA vs CDAHFD/IgG); NS=  
 $p > 0.05$



WORLDWIDE RESEARCH & DEVELOPMENT  
Drug Safety R&D

Cirrhotic liver excluded

SCIENCE LIFE-CHANGING  
FOR IMPACT

# Summary

- Both triple combination treatments reduced liver index at 12-wk time point.
- No effect on liver enzymes from any treatments.
- All treatments (dual, both IL4 and TGFb triple combination) showed reduction of SWE signal at 12-week time point, whereas histologically, only TGFb triple combination showed significantly attenuated PSR and a-SMA.



WORLDWIDE RESEARCH & DEVELOPMENT  
Drug Safety R&D

SCIENCE  LIFE-CHANGING  
FOR IMPACT

# Samples selected for RNAseq

- 6 samples from each group 1 to 5.
- Sample ID TBD.

Group ID	Animal ID	Diet	Compound	route	Duration
1	1_12	chow	none		12 wk
2	14_24	CDAHFD	mIgGs		12 wk
3	25_36	CDAHFD	sIL13Ra2, anti-p40		12 wk
4	37_44, 49_52	CDAHFD	anti-IL4, sIL13Ra2, anti-p40		12 wk
5	46_48, 53_60	CDAHFD	sIL13Ra2, anti-p40, anti-TGF-b	subQ, 2x/wk	12 wk
6	61_67	CDAHFD	none		4 wk

